|
|
ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain
|
|
Insights into Smoldering (Asymptomatic) Multiple Myeloma
What is Smoldering Myeloma?
ASH 2011: Dr. Mateos - Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
High-Risk Smoldering Myeloma Addressed by Group 1 during Second Annual International Myeloma Working Group Summit
|
|
|
An ASCO Connection Current Controversies in Oncology article featuring Dr. Kyle of the Mayo Clinic. |
|
|
|
|
Dr. Ola Landgren
National Cancer Institute
Bethesda, Maryland |
|
|
|
|
|
María-Victoria Mateos, MD, PhD
Hospital Clinico Universitario
Salamanca, Spain |
|
|
|
|
|
How to maximize benefits of early treatment for patients with high-risk smoldering myeloma, yet avoid unnecessary treatment and toxicities. |
|
|
back
print
related articles
Be the first to comment